Literature DB >> 23165507

Falls in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

L D Facchinetti1, A Q Araújo, G L Chequer, M F de Azevedo, R V C de Oliveira, M A Lima.   

Abstract

STUDY
DESIGN: Cross-sectional study.
OBJECTIVES: To determine the prevalence of falls in human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients and possible factors associated to their occurrence.
SETTING: Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz (FIOCRUZ) - Brazil.
METHODS: Thirty-six HAM/TSP patients able to walk at least 20 m were assessed by a questionnaire. Data regarding gender, age, duration of disease (DD), HTLV-I proviral load (HPL), frequency of physical activity (FCA), use of walking aids, functional ambulation level, the number of falls and associated injuries in the last year were reviewed. Multiple correspondence analysis was used to group characteristics of this sample according to the fall occurrence.
RESULTS: The prevalence of falls was 63.9% and we observed injuries in 47.8% of the cases. Four groups were identified in the descriptive analysis. One group was formed by faller individuals, men <60 years, independent ambulation, FCA≥3 times per week and HPL <6.6 copies per 100 cells (group B). The other one comprised non-faller patients, women ≥60 years, restricted ambulation, DD ≥7 years, use of orthosis, FCA 0-1 time per week and HPL ≥6.6 copies per 100 cells (group D). The others two groups comprised individuals that did not use orthosis (group A) and those that FCA was two times per week and DD <7 years (group C).
CONCLUSION: Falls occur in roughly two-thirds of ambulatory HAM/TSP patients and are associated with significant morbidity. Further studies with a larger number of patients are necessarily to identify risk factors in order to elaborate specific programs to prevent falls in this population.

Entities:  

Mesh:

Year:  2012        PMID: 23165507     DOI: 10.1038/sc.2012.134

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  9 in total

1.  HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012).

Authors:  Gregorio González-Alcaide; José Manuel Ramos; Charles Huamaní; Carmen de Mendoza; Vicent Soriano
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-02-23       Impact factor: 1.846

2.  Neurological manifestations in individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis in the Amazon.

Authors:  G A S Dias; G T Yoshikawa; R V L Koyama; S Fujihara; L C S Martins; R Medeiros; J A S Quaresma; H T Fuzii
Journal:  Spinal Cord       Date:  2015-07-14       Impact factor: 2.772

Review 3.  Physiotherapy for human T-lymphotropic virus 1-associated myelopathy: review of the literature and future perspectives.

Authors:  Katia N Sá; Maíra C Macêdo; Rosana P Andrade; Selena D Mendes; José V Martins; Abrahão F Baptista
Journal:  J Multidiscip Healthc       Date:  2015-02-23

4.  Experienced complaints, activity limitations and loss of motor capacities in patients with pure hereditary spastic paraplegia: a web-based survey in the Netherlands.

Authors:  Bas J H van Lith; Hans C J W Kerstens; Laura A C van den Bemd; Maria W G Nijhuis-van der Sanden; Vivian Weerdesteyn; Rob J E M Smeets; Klemens Fheodoroff; Bart P C van de Warrenburg; Alexander C H Geurts
Journal:  Orphanet J Rare Dis       Date:  2020-03-04       Impact factor: 4.123

5.  Therapeutic effects of virtual reality video gaming on functional mobility, balance, and gait speed in individuals with tropical spastic paraparesis: A randomized crossover clinical trial.

Authors:  Erika Pedreira da Fonseca; Katia Nunes Sá; Rebeca Freitas Reis Nunes; Camille Rosa de Jesus Souza; Mayra Castro de Matos Sousa; Elen Beatriz Pinto
Journal:  Rev Soc Bras Med Trop       Date:  2021-01-29       Impact factor: 1.581

6.  Balance assessment in HTLV-1 associated myelopathy or tropical spastic paraparesis.

Authors:  Naiane Araújo Patrício; Mônica Andrade Rios; Patrícia Carvalho Barbosa; Jéssica Ramos Ribeiro; Diogo Guedes Vidal; Kátia Nunes Sá; Abrahão Fontes Baptista
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-25       Impact factor: 1.581

7.  Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.

Authors:  Flávia Dos Santos Souza; Nicole Lardini Freitas; Yago Côrtes Pinheiro Gomes; Rafael Carvalho Torres; Juliana Echevarria-Lima; Isaac Lima da Silva-Filho; Ana Claudia Celestino Bezerra Leite; Marco Antonio Sales Dantas de Lima; Marcus Tulius Teixeira da Silva; Abelardo de Queiroz Campos Araújo; Otávio Melo Espíndola
Journal:  Front Immunol       Date:  2021-10-26       Impact factor: 7.561

8.  Assessing Walking Ability in People with HTLV-1-Associated Myelopathy Using the 10 Meter Timed Walk and the 6 Minute Walk Test.

Authors:  Adine Adonis; Graham P Taylor
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

9.  Impact of fractures and orthopedic surgeries in patients with HTLV-1 associated myelopathy/tropical spastic paraparesis.

Authors:  Pablo Julca-Copello; Alvaro Schwalb; Rodrigo Cachay; Martín Tipismana; Carolina Alvarez; Fernando Mejía; Elsa González-Lagos; Eduardo Gotuzzo
Journal:  Rev Soc Bras Med Trop       Date:  2020-09-11       Impact factor: 1.581

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.